{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:30:04Z","timestamp":1785796204710,"version":"3.56.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s10072-020-04514-2","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T15:04:09Z","timestamp":1592406249000},"page":"3085-3098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Current application of cannabidiol (CBD) in the management and treatment of neurological disorders"],"prefix":"10.1007","volume":"41","author":[{"given":"Brian","family":"Fiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasra John","family":"Sarhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Soula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-1847","authenticated-orcid":false,"given":"Syed A.","family":"Quadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"issue":"9","key":"4514_CR1","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1056\/NEJMc1407928","volume":"371","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 371(9):878\u2013879. https:\/\/doi.org\/10.1056\/NEJMc1407928","journal-title":"N Engl J Med"},{"issue":"3","key":"4514_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamapsychiatry.2015.3278","volume":"73","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 73(3):292\u2013297. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.3278","journal-title":"JAMA Psychiatry"},{"key":"4514_CR3","doi-asserted-by":"publisher","first-page":"5313795","DOI":"10.1155\/2016\/5313795","volume":"2016","author":"M Jamil","year":"2016","unstructured":"Jamil M, Zafar A, Adeel Faizi S, Zawar I (2016) Stroke from vasospasm due to marijuana use: can cannabis synergistically with other medications trigger cerebral vasospasm? Case Rep Neurol Med 2016:5313795\u20135313794. https:\/\/doi.org\/10.1155\/2016\/5313795","journal-title":"Case Rep Neurol Med"},{"issue":"4","key":"4514_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a cannabis sativa constituent. Curr Drug Saf 6(4):237\u2013249. https:\/\/doi.org\/10.2174\/157488611798280924","journal-title":"Curr Drug Saf"},{"issue":"02","key":"4514_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1055\/s-0042-100702","volume":"17","author":"F Grotenhermen","year":"2016","unstructured":"Grotenhermen F, M\u00fcller-Vahl K (2016) Cannabis und cannabinoide in der medizin: fakten und ausblick. Suchttherapie 17(02):71\u201376. https:\/\/doi.org\/10.1055\/s-0042-100702","journal-title":"Suchttherapie"},{"issue":"14","key":"4514_CR6","doi-asserted-by":"publisher","first-page":"8268","DOI":"10.1073\/pnas.95.14.8268","volume":"95","author":"AJ Hampson","year":"1998","unstructured":"Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (\u2212)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95(14):8268\u20138273. https:\/\/doi.org\/10.1073\/pnas.95.14.8268","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"4514_CR7","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1172\/jci64628","volume":"124","author":"A Ol\u00e1h","year":"2014","unstructured":"Ol\u00e1h A, T\u00f3th BI, Borb\u00edr\u00f3 I, Sugawara K, Sz\u00f6ll\u00f5si AG, Czifra G, P\u00e1l B, Ambrus L, Kloepper J, Camera E, Ludovici M, Picardo M, Voets T, Zouboulis CC, Paus R, B\u00edr\u00f3 T (2014) Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Investig 124(9):3713\u20133724. https:\/\/doi.org\/10.1172\/jci64628","journal-title":"J Clin Investig"},{"issue":"1","key":"4514_CR8","first-page":"34","volume":"110","author":"TH Mikuriya","year":"1969","unstructured":"Mikuriya TH (1969) Marijuana in medicine: past, present and future. Calif Med 110(1):34\u201340","journal-title":"Calif Med"},{"key":"4514_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","volume":"175","author":"S Pisanti","year":"2017","unstructured":"Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M (2017) Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther 175:133\u2013150. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.041","journal-title":"Pharmacol Ther"},{"issue":"12","key":"4514_CR10","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","volume":"19","author":"R Mechoulam","year":"1963","unstructured":"Mechoulam R, Shvo Y (1963) Hashish\u2014I: the structure of cannabidiol. Tetrahedron 19(12):2073\u20132078","journal-title":"Tetrahedron"},{"issue":"5","key":"4514_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ptr.2625","volume":"23","author":"C Scuderi","year":"2009","unstructured":"Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009) Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res 23(5):597\u2013602. https:\/\/doi.org\/10.1002\/ptr.2625","journal-title":"Phytother Res"},{"issue":"1","key":"4514_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/1535-7163.MCT-12-0335","volume":"12","author":"R Ramer","year":"2013","unstructured":"Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, Hinz B (2013) COX-2 and PPAR-gamma confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther 12(1):69\u201382. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0335","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"4514_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","volume":"74","author":"RG Pertwee","year":"1997","unstructured":"Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74(2):129\u2013180","journal-title":"Pharmacol Ther"},{"issue":"5","key":"4514_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1517\/14728222.10.5.653","volume":"10","author":"CA Lunn","year":"2006","unstructured":"Lunn CA, Reich EP, Bober L (2006) Targeting the CB2 receptor for immune modulation. Expert Opin Ther Targets 10(5):653\u2013663. https:\/\/doi.org\/10.1517\/14728222.10.5.653","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"4514_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfj034","volume":"89","author":"B Veronesi","year":"2006","unstructured":"Veronesi B, Oortgiesen M (2006) The TRPV1 receptor: target of toxicants and therapeutics. Toxicol Sci 89(1):1\u20133. https:\/\/doi.org\/10.1093\/toxsci\/kfj034","journal-title":"Toxicol Sci"},{"key":"4514_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","volume":"71","author":"MR Pazos","year":"2013","unstructured":"Pazos MR, Mohammed N, Lafuente H, Santos M, Martinez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martinez-Orgado J (2013) Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology 71:282\u2013291. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.03.027","journal-title":"Neuropharmacology"},{"issue":"3","key":"4514_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00213-007-0970-1","volume":"196","author":"EM Rock","year":"2008","unstructured":"Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA (2008) The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology 196(3):389\u2013395. https:\/\/doi.org\/10.1007\/s00213-007-0970-1","journal-title":"Psychopharmacology"},{"issue":"2","key":"4514_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.bbr.2010.05.004","volume":"213","author":"P Soares Vde","year":"2010","unstructured":"Soares Vde P, Campos AC, Bortoli VC, Zangrossi H Jr, Guimaraes FS, Zuardi AW (2010) Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res 213(2):225\u2013229. https:\/\/doi.org\/10.1016\/j.bbr.2010.05.004","journal-title":"Behav Brain Res"},{"issue":"6","key":"4514_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/1060028018822124","volume":"53","author":"JW Chen","year":"2019","unstructured":"Chen JW, Borgelt LM, Blackmer AB (2019) Cannabidiol: a new hope for patients with Dravet or Lennox-Gastaut syndromes. Ann Pharmacother 53(6):603\u2013611. https:\/\/doi.org\/10.1177\/1060028018822124","journal-title":"Ann Pharmacother"},{"issue":"9","key":"4514_CR20","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/bdd.2510110906","volume":"11","author":"E Samara","year":"1990","unstructured":"Samara E, Bialer M, Harvey DJ (1990) Pharmacokinetics of urinary metabolites of cannabidiol in the dog. Biopharm Drug Dispos 11(9):785\u2013795","journal-title":"Biopharm Drug Dispos"},{"issue":"13","key":"4514_CR21","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1503\/cmaj.071178","volume":"178","author":"T Wang","year":"2008","unstructured":"Wang T, Collet JP, Shapiro S, Ware MA (2008) Adverse effects of medical cannabinoids: a systematic review. CMAJ 178(13):1669\u20131678. https:\/\/doi.org\/10.1503\/cmaj.071178","journal-title":"CMAJ"},{"key":"4514_CR22","doi-asserted-by":"publisher","unstructured":"Mead A (2016) The legal and regulatory status of cannabidiol (CBD). Planta Med 82(05). https:\/\/doi.org\/10.1055\/s-0036-1578585","DOI":"10.1055\/s-0036-1578585"},{"issue":"Pt B","key":"4514_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.yebeh.2016.11.021","volume":"70","author":"A Mead","year":"2017","unstructured":"Mead A (2017) The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav 70(Pt B):288\u2013291. https:\/\/doi.org\/10.1016\/j.yebeh.2016.11.021","journal-title":"Epilepsy Behav"},{"issue":"1","key":"4514_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40122-019-0114-4","volume":"8","author":"I Urits","year":"2019","unstructured":"Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O (2019) An update of current cannabis-based pharmaceuticals in pain medicine. Pain Ther 8(1):41\u201351. https:\/\/doi.org\/10.1007\/s40122-019-0114-4","journal-title":"Pain Ther"},{"issue":"1\u20133","key":"4514_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.pain.2007.08.028","volume":"133","author":"TJ Nurmikko","year":"2007","unstructured":"Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D (2007) Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133(1\u20133):210\u2013220. https:\/\/doi.org\/10.1016\/j.pain.2007.08.028","journal-title":"Pain"},{"key":"4514_CR26","volume-title":"CADTH Rapid Response Reports","author":"CADTH rapid response reports","year":"2016","unstructured":"CADTH rapid response reports (2016) Cannabinoid buccal spray for chronic non-cancer or neuropathic pain: a review of clinical effectiveness, safety, and guidelines. In: CADTH Rapid Response Reports. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)"},{"issue":"1","key":"4514_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/kei183","volume":"45","author":"DR Blake","year":"2006","unstructured":"Blake DR, Robson P, Ho M, Jubb RW, McCabe CS (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45(1):50\u201352. https:\/\/doi.org\/10.1093\/rheumatology\/kei183","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"4514_CR28","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s13311-015-0367-5","volume":"12","author":"S Arjmand","year":"2015","unstructured":"Arjmand S, Vaziri Z, Behzadi M, Abbassian H, Stephens GJ, Shabani M (2015) Cannabinoids and tremor induced by motor-related disorders: friend or foe? Neurotherapeutics 12(4):778\u2013787. https:\/\/doi.org\/10.1007\/s13311-015-0367-5","journal-title":"Neurotherapeutics"},{"issue":"4","key":"4514_CR29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","volume":"12","author":"C Ibeas Bih","year":"2015","unstructured":"Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ (2015) Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12(4):699\u2013730. https:\/\/doi.org\/10.1007\/s13311-015-0377-3","journal-title":"Neurotherapeutics"},{"issue":"22","key":"4514_CR30","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1111\/bph.13581","volume":"173","author":"H Abbassian","year":"2016","unstructured":"Abbassian H, Whalley BJ, Sheibani V, Shabani M (2016) Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. Br J Pharmacol 173(22):3196\u20133207. https:\/\/doi.org\/10.1111\/bph.13581","journal-title":"Br J Pharmacol"},{"issue":"9","key":"4514_CR31","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00702-009-0254-5","volume":"116","author":"W Kolasiewicz","year":"2009","unstructured":"Kolasiewicz W, Kuter K, Wardas J, Ossowska K (2009) Role of the metabotropic glutamate receptor subtype 1 in the harmaline-induced tremor in rats. J Neural Transm (Vienna) 116(9):1059\u20131063. https:\/\/doi.org\/10.1007\/s00702-009-0254-5","journal-title":"J Neural Transm (Vienna)"},{"key":"4514_CR32","doi-asserted-by":"publisher","unstructured":"Handforth A (2012) Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor. Tremor Other Hyperkinet Mov (N Y) 2. https:\/\/doi.org\/10.7916\/D8TD9W2P","DOI":"10.7916\/D8TD9W2P"},{"issue":"1","key":"4514_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1755-5949.2008.00065.x","volume":"15","author":"T Iuvone","year":"2009","unstructured":"Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L (2009) Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 15(1):65\u201375. https:\/\/doi.org\/10.1111\/j.1755-5949.2008.00065.x","journal-title":"CNS Neurosci Ther"},{"issue":"1\u20132","key":"4514_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","volume":"19","author":"I Lastres-Becker","year":"2005","unstructured":"Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19(1\u20132):96\u2013107. https:\/\/doi.org\/10.1016\/j.nbd.2004.11.009","journal-title":"Neurobiol Dis"},{"issue":"6","key":"4514_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(16)00120-4","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D (2016) Cannabidiol in patients with treatment-resistant epilepsy - Authors' reply. Lancet Neurol 15(6):545\u2013546. https:\/\/doi.org\/10.1016\/S1474-4422(16)00120-4","journal-title":"Lancet Neurol"},{"key":"4514_CR36","unstructured":"Laurie K Mischley N (2019) Cannabis and Parkinson's disease tremor: a natural history study. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02028858"},{"issue":"4","key":"4514_CR37","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12(4):825\u2013836. https:\/\/doi.org\/10.1007\/s13311-015-0387-1","journal-title":"Neurotherapeutics"},{"issue":"3","key":"4514_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00432554","volume":"76","author":"AW Zuardi","year":"1982","unstructured":"Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76(3):245\u2013250","journal-title":"Psychopharmacology"},{"issue":"1 Suppl","key":"4514_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","volume":"7","author":"AW Zuardi","year":"1993","unstructured":"Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7(1 Suppl):82\u201388. https:\/\/doi.org\/10.1177\/026988119300700112","journal-title":"J Psychopharmacol"},{"key":"4514_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.biocel.2014.08.007","volume":"55","author":"P McDonough","year":"2014","unstructured":"McDonough P, McKenna JP, McCreary C, Downer EJ (2014) Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. Int J Biochem Cell Biol 55:72\u201378. https:\/\/doi.org\/10.1016\/j.biocel.2014.08.007","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"4514_CR41","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/jcpt.12179","volume":"39","author":"MH Chagas","year":"2014","unstructured":"Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA (2014) Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther 39(5):564\u2013566. https:\/\/doi.org\/10.1111\/jcpt.12179","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"4514_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000112901","volume":"38","author":"P Consroe","year":"1997","unstructured":"Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38(1):44\u201348. https:\/\/doi.org\/10.1159\/000112901","journal-title":"Eur Neurol"},{"issue":"1","key":"4514_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13643-019-0990-z","volume":"8","author":"J Elliott","year":"2019","unstructured":"Elliott J, McCoy B, Clifford T, Potter BK, Skidmore B, Wells GA, Coyle D (2019) Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. Syst Rev 8(1):75. https:\/\/doi.org\/10.1186\/s13643-019-0990-z","journal-title":"Syst Rev"},{"issue":"1","key":"4514_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neuropharm.2007.04.019","volume":"53","author":"YC Liang","year":"2007","unstructured":"Liang YC, Huang CC, Hsu KS (2007) The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology 53(1):169\u2013177. https:\/\/doi.org\/10.1016\/j.neuropharm.2007.04.019","journal-title":"Neuropharmacology"},{"key":"4514_CR45","volume-title":"Classification of chronic pain: description of chronic pain syndromes and definitions of pain terms","author":"D Harold Merskey","year":"1994","unstructured":"Harold Merskey D (1994) Classification of chronic pain: description of chronic pain syndromes and definitions of pain terms, 2nd edn. IASP PRESS, Seattle","edition":"2"},{"key":"4514_CR46","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2147\/JPR.S166617","volume":"11","author":"E Mondello","year":"2018","unstructured":"Mondello E, Quattrone D, Cardia L, Bova G, Mallamace R, Barbagallo AA, Mondello C, Mannucci C, Di Pietro M, Arcoraci V, Calapai G (2018) Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain. J Pain Res 11:1761\u20131767. https:\/\/doi.org\/10.2147\/JPR.S166617","journal-title":"J Pain Res"},{"issue":"22","key":"4514_CR47","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa064039","volume":"356","author":"WC Peul","year":"2007","unstructured":"Peul WC, van Houwelingen HC, van den Hout WB, Brand R, Eekhof JA, Tans JT, Thomeer RT, Koes BW, Leiden-The Hague Spine Intervention Prognostic Study G (2007) Surgery versus prolonged conservative treatment for sciatica. N Engl J Med 356(22):2245\u20132256. https:\/\/doi.org\/10.1056\/NEJMoa064039","journal-title":"N Engl J Med"},{"issue":"9313","key":"4514_CR48","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","volume":"359","author":"A Compston","year":"2002","unstructured":"Compston A, Coles A (2002) Multiple sclerosis. Lancet 359(9313):1221\u20131231. https:\/\/doi.org\/10.1016\/S0140-6736(02)08220-X","journal-title":"Lancet"},{"key":"4514_CR49","first-page":"1","volume":"72","author":"C Perras","year":"2005","unstructured":"Perras C (2005) Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 72:1\u20134","journal-title":"Issues Emerg Health Technol"},{"issue":"17","key":"4514_CR50","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","volume":"82","author":"BS Koppel","year":"2014","unstructured":"Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82(17):1556\u20131563. https:\/\/doi.org\/10.1212\/WNL.0000000000000363","journal-title":"Neurology"},{"issue":"3","key":"4514_CR51","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0091-3057(91)90357-8","volume":"40","author":"P Consroe","year":"1991","unstructured":"Consroe P, Kennedy K, Schram K (1991) Assay of plasma cannabidiol by capillary gas chromatography\/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav 40(3):517\u2013522","journal-title":"Pharmacol Biochem Behav"},{"key":"4514_CR52","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.yebeh.2015.04.009","volume":"47","author":"SA Hussain","year":"2015","unstructured":"Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R (2015) Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav 47:138\u2013141. https:\/\/doi.org\/10.1016\/j.yebeh.2015.04.009","journal-title":"Epilepsy Behav"},{"issue":"4","key":"4514_CR53","first-page":"4","volume":"5","author":"R Kurz","year":"2010","unstructured":"Kurz R, Blaas K (2010) Use of dronabinol (delta-9-THC) in autism: a prospective single-case-study with an early infantile autistic child. Cannabinoids 5(4):4\u20136","journal-title":"Cannabinoids"},{"issue":"3","key":"4514_CR54","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3390\/brainsci3031043","volume":"3","author":"D Fernandez-Lopez","year":"2013","unstructured":"Fernandez-Lopez D, Lizasoain I, Moro MA, Martinez-Orgado J (2013) Cannabinoids: well-suited candidates for the treatment of perinatal brain injury. Brain Sci 3(3):1043\u20131059. https:\/\/doi.org\/10.3390\/brainsci3031043","journal-title":"Brain Sci"},{"issue":"2","key":"4514_CR55","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.3747\/co.23.2893","volume":"23","author":"T Fisher","year":"2016","unstructured":"Fisher T, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R, Mechoulam R, Toren A (2016) In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol 23(2):S15\u2013S22. https:\/\/doi.org\/10.3747\/co.23.2893","journal-title":"Curr Oncol"},{"issue":"23","key":"4514_CR56","doi-asserted-by":"publisher","first-page":"9800","DOI":"10.1073\/pnas.0703472104","volume":"104","author":"HD Burns","year":"2007","unstructured":"Burns HD, Van Laere K, Sanabria-Bohorquez S, Hamill TG, Bormans G, Eng WS, Gibson R, Ryan C, Connolly B, Patel S, Krause S, Vanko A, Van Hecken A, Dupont P, De Lepeleire I, Rothenberg P, Stoch SA, Cote J, Hagmann WK, Jewell JP, Lin LS, Liu P, Goulet MT, Gottesdiener K, Wagner JA, de Hoon J, Mortelmans L, Fong TM, Hargreaves RJ (2007) [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104(23):9800\u20139805. https:\/\/doi.org\/10.1073\/pnas.0703472104","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4514_CR57","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/chi.0b013e31802dc54d","volume":"46","author":"MR Hayatbakhsh","year":"2007","unstructured":"Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W (2007) Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry 46(3):408\u2013417. https:\/\/doi.org\/10.1097\/chi.0b013e31802dc54d","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"4514_CR58","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1192\/bjp.bp.110.077479","volume":"198","author":"MA Fontes","year":"2011","unstructured":"Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL (2011) Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry 198(6):442\u2013447. https:\/\/doi.org\/10.1192\/bjp.bp.110.077479","journal-title":"Br J Psychiatry"},{"key":"4514_CR59","doi-asserted-by":"publisher","unstructured":"Batalla A, Janssen H, Gangadin SS, Bossong MG (2019) The potential of Cannabidiol as a treatment for psychosis and addiction: who benefits Most? A systematic review. J Clin Med 8(7). https:\/\/doi.org\/10.3390\/jcm8071058","DOI":"10.3390\/jcm8071058"},{"issue":"32","key":"4514_CR60","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.2174\/138161212802884681","volume":"18","author":"AW Zuardi","year":"2012","unstructured":"Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimaraes FS (2012) A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 18(32):5131\u20135140. https:\/\/doi.org\/10.2174\/138161212802884681","journal-title":"Curr Pharm Des"},{"issue":"8","key":"4514_CR61","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.3390\/ph3082689","volume":"3","author":"S Walther","year":"2010","unstructured":"Walther S, Halpern M (2010) Cannabinoids and dementia: a review of clinical and preclinical data. Pharmaceuticals 3(8):2689\u20132708. https:\/\/doi.org\/10.3390\/ph3082689","journal-title":"Pharmaceuticals"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04514-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-020-04514-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04514-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:03:28Z","timestamp":1623801808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-020-04514-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4514"],"URL":"https:\/\/doi.org\/10.1007\/s10072-020-04514-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"10 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a review which did not include any human research subject participation. Therefore, no informed consent or ethical approval was required for this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}